[Skip to Content]
[Skip to Content Landing]
Views 789
Citations 0
Viewpoint
September 2017

Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease RiskWhere Do We Stand?

Author Affiliations
  • 1Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • 2Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
JAMA Cardiol. 2017;2(9):937-938. doi:10.1001/jamacardio.2017.2288

It is remarkable that we continue to see challenges to the LDL hypothesis and that we also seem to need monographs defending it.1 How is it possible that we are still debating the empirical facts that low-density lipoprotein (LDL) cholesterol, or, more appropriately, apolipoprotein B–containing lipid particles, are the central actors in atherogenesis and that lowering LDL cholesterol with therapies that are proven safe and efficacious is one of our most effective strategies?

First Page Preview View Large
First page PDF preview
First page PDF preview
×